These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33368145)

  • 1. Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey.
    Mahil SK; Yates M; Langan SM; Yiu ZZN; Tsakok T; Dand N; Mason KJ; McAteer H; Meynell F; Coker B; Vincent A; Urmston D; Vesty A; Kelly J; Lancelot C; Moorhead L; Bachelez H; Bruce IN; Capon F; Contreras CR; Cope AP; De La Cruz C; Di Meglio P; Gisondi P; Hyrich K; Jullien D; Lambert J; Marzo-Ortega H; McInnes I; Naldi L; Norton S; Puig L; Sengupta R; Spuls P; Torres T; Warren RB; Waweru H; Weinman J; Griffiths CEM; Barker JN; Brown MA; Galloway JB; Smith CH;
    Br J Dermatol; 2021 Jul; 185(1):80-90. PubMed ID: 33368145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonadherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey.
    Quirke-McFarlane S; Weinman J; Cook ES; Yiu ZZN; Dand N; Langan SM; Bechman K; Tsakok T; Mason KJ; McAteer H; Meynell F; Coker B; Vincent A; Urmston D; Vesty A; Kelly J; Lancelot C; Moorhead L; Barbosa IA; Bachelez H; Capon F; Contreras CR; De La Cruz C; Di Meglio P; Gisondi P; Jullien D; Lambert J; Naldi L; Puig L; Spuls P; Torres T; Warren RB; Waweru H; Galloway JB; Griffiths CEM; Barker JN; Norton S; Smith CH; Mahil SK;
    Br J Dermatol; 2023 Apr; 188(5):610-617. PubMed ID: 36763806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19.
    Izadi Z; Brenner EJ; Mahil SK; Dand N; Yiu ZZN; Yates M; Ungaro RC; Zhang X; Agrawal M; Colombel JF; Gianfrancesco MA; Hyrich KL; Strangfeld A; Carmona L; Mateus EF; Lawson-Tovey S; Klingberg E; Cuomo G; Caprioli M; Cruz-Machado AR; Mazeda Pereira AC; Hasseli R; Pfeil A; Lorenz HM; Hoyer BF; Trupin L; Rush S; Katz P; Schmajuk G; Jacobsohn L; Seet AM; Al Emadi S; Wise L; Gilbert EL; Duarte-García A; Valenzuela-Almada MO; Isnardi CA; Quintana R; Soriano ER; Hsu TY; D'Silva KM; Sparks JA; Patel NJ; Xavier RM; Marques CDL; Kakehasi AM; Flipo RM; Claudepierre P; Cantagrel A; Goupille P; Wallace ZS; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Robinson PC; Machado PM; Griffiths CEM; Barker JN; Smith CH; Yazdany J; Kappelman MD; ;
    JAMA Netw Open; 2021 Oct; 4(10):e2129639. PubMed ID: 34661663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study.
    Mahil SK; Dand N; Mason KJ; Yiu ZZN; Tsakok T; Meynell F; Coker B; McAteer H; Moorhead L; Mackenzie T; Rossi MT; Rivera R; Mahe E; Carugno A; Magnano M; Rech G; Balogh EA; Feldman SR; De La Cruz C; Choon SE; Naldi L; Lambert J; Spuls P; Jullien D; Bachelez H; McMahon DE; Freeman EE; Gisondi P; Puig L; Warren RB; Di Meglio P; Langan SM; Capon F; Griffiths CEM; Barker JN; Smith CH;
    J Allergy Clin Immunol; 2021 Jan; 147(1):60-71. PubMed ID: 33075408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID).
    Kwee KV; Murk JL; Yin Q; Visch MB; Davidson L; de Jong EMGJ; van den Reek JMPA; Tjioe M
    J Dermatolog Treat; 2023 Dec; 34(1):2161297. PubMed ID: 36545844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of the COVID-19 pandemic on people with rheumatic and musculoskeletal diseases: insights from patient-generated data on social media.
    Reuter K; Deodhar A; Makri S; Zimmer M; Berenbaum F; Nikiphorou E
    Rheumatology (Oxford); 2021 Oct; 60(SI):SI77-SI84. PubMed ID: 33629107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors associated with SARS-CoV-2 infection in a multiethnic cohort of United Kingdom healthcare workers (UK-REACH): A cross-sectional analysis.
    Martin CA; Pan D; Melbourne C; Teece L; Aujayeb A; Baggaley RF; Bryant L; Carr S; Gregary B; Gupta A; Guyatt AL; John C; McManus IC; Nazareth J; Nellums LB; Reza R; Simpson S; Tobin MD; Woolf K; Zingwe S; Khunti K; Abrams KR; Gray LJ; Pareek M;
    PLoS Med; 2022 May; 19(5):e1004015. PubMed ID: 35617423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of and Risk Factors Associated With Mental Health Symptoms Among the General Population in China During the Coronavirus Disease 2019 Pandemic.
    Shi L; Lu ZA; Que JY; Huang XL; Liu L; Ran MS; Gong YM; Yuan K; Yan W; Sun YK; Shi J; Bao YP; Lu L
    JAMA Netw Open; 2020 Jul; 3(7):e2014053. PubMed ID: 32609353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody tests for identification of current and past infection with SARS-CoV-2.
    Deeks JJ; Dinnes J; Takwoingi Y; Davenport C; Spijker R; Taylor-Phillips S; Adriano A; Beese S; Dretzke J; Ferrante di Ruffano L; Harris IM; Price MJ; Dittrich S; Emperador D; Hooft L; Leeflang MM; Van den Bruel A;
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013652. PubMed ID: 32584464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody tests for identification of current and past infection with SARS-CoV-2.
    Fox T; Geppert J; Dinnes J; Scandrett K; Bigio J; Sulis G; Hettiarachchi D; Mathangasinghe Y; Weeratunga P; Wickramasinghe D; Bergman H; Buckley BS; Probyn K; Sguassero Y; Davenport C; Cunningham J; Dittrich S; Emperador D; Hooft L; Leeflang MM; McInnes MD; Spijker R; Struyf T; Van den Bruel A; Verbakel JY; Takwoingi Y; Taylor-Phillips S; Deeks JJ;
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013652. PubMed ID: 36394900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
    Singh B; Ryan H; Kredo T; Chaplin M; Fletcher T
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013587. PubMed ID: 33624299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Rapid Online Surveys to Assess People's Perceptions During Infectious Disease Outbreaks: A Cross-sectional Survey on COVID-19.
    Geldsetzer P
    J Med Internet Res; 2020 Apr; 22(4):e18790. PubMed ID: 32240094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Janus kinase inhibitors for the treatment of COVID-19.
    Kramer A; Prinz C; Fichtner F; Fischer AL; Thieme V; Grundeis F; Spagl M; Seeber C; Piechotta V; Metzendorf MI; Golinski M; Moerer O; Stephani C; Mikolajewska A; Kluge S; Stegemann M; Laudi S; Skoetz N
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD015209. PubMed ID: 35695334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remdesivir for the treatment of COVID-19.
    Grundeis F; Ansems K; Dahms K; Thieme V; Metzendorf MI; Skoetz N; Benstoem C; Mikolajewska A; Griesel M; Fichtner F; Stegemann M
    Cochrane Database Syst Rev; 2023 Jan; 1(1):CD014962. PubMed ID: 36695483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of COVID-19 pandemic social restriction measures on people with rheumatic and musculoskeletal diseases in the UK: a mixed-methods study.
    Smith TO; Belderson P; Dainty JR; Birt L; Durrant K; Chipping JR; Tsigarides J; Yates M; Naughton F; Werry S; Notley C; Shepstone L; MacGregor AJ
    BMJ Open; 2021 Jun; 11(6):e048772. PubMed ID: 34083347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform.
    MacKenna B; Kennedy NA; Mehrkar A; Rowan A; Galloway J; Matthewman J; Mansfield KE; Bechman K; Yates M; Brown J; Schultze A; Norton S; Walker AJ; Morton CE; Harrison D; Bhaskaran K; Rentsch CT; Williamson E; Croker R; Bacon S; Hickman G; Ward T; Davy S; Green A; Fisher L; Hulme W; Bates C; Curtis HJ; Tazare J; Eggo RM; Evans D; Inglesby P; Cockburn J; McDonald HI; Tomlinson LA; Mathur R; Wong AYS; Forbes H; Parry J; Hester F; Harper S; Douglas IJ; Smeeth L; Lees CW; Evans SJW; Goldacre B; Smith CH; Langan SM
    Lancet Rheumatol; 2022 Jul; 4(7):e490-e506. PubMed ID: 35698725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
    Gianfrancesco M; Hyrich KL; Al-Adely S; Carmona L; Danila MI; Gossec L; Izadi Z; Jacobsohn L; Katz P; Lawson-Tovey S; Mateus EF; Rush S; Schmajuk G; Simard J; Strangfeld A; Trupin L; Wysham KD; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Wallace ZS; Yazdany J; Machado PM; Robinson PC;
    Ann Rheum Dis; 2020 Jul; 79(7):859-866. PubMed ID: 32471903
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.